Goldman Sachs Maintains Buy on Sagimet Biosciences, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Andrea Tan has reaffirmed a Buy rating on Sagimet Biosciences (NASDAQ:SGMT) and increased the price target from $30 to $37, indicating a positive outlook on the company's stock.
January 23, 2024 | 2:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Andrea Tan maintains a Buy rating on Sagimet Biosciences and raises the price target from $30 to $37, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst from Goldman Sachs typically signals a strong conviction in the company's growth prospects and financial health. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100